The estimated Net Worth of N Anthony Coles is at least $9.08 Million dollars as of 28 December 2022. N Coles owns over 5,758 units of Regeneron Pharmaceuticals stock worth over $7,820,074 and over the last 21 years he sold REGN stock worth over $558,288. In addition, he makes $704,993 as Independent Director at Regeneron Pharmaceuticals.
N has made over 8 trades of the Regeneron Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 5,758 units of REGN stock worth $2,546,418 on 28 December 2022.
The largest trade he's ever made was exercising 11,948 units of Regeneron Pharmaceuticals stock on 15 September 2021 worth over $4,372,849. On average, N trades about 888 units every 40 days since 2003. As of 28 December 2022 he still owns at least 6,851 units of Regeneron Pharmaceuticals stock.
You can see the complete history of N Coles stock trades at the bottom of the page.
Dr. N. Anthony Coles Jr., M.D. serves as Independent Director of the Company. He has served as the Executive Chairman and Chief Executive Officer of Cerevel Therapeutics, LLC, a Bain-portfolio biotechnology company specializing in the development of new therapies for diseases of the central nervous system, since 2019. Previously, from 2014 to 2019, Dr. Coles served as Chief Executive Officer of Yumanity Therapeutics, LLC, a private company focused on transforming drug discovery for neurodegenerative diseases, and continues to serve as the Executive Chairman of the Board. From 2013 to 2014, Dr. Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately held company. Dr. Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until 2013, having served as its President, Chief Executive Officer, and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc., a biopharmaceutical company. Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company, and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings, Campus Crest Communities, Inc., and CRISPR Therapeutics AG. Dr. Coles has been a director of McKesson Corporation since April 2014 and serves on the Compensation Committee and the Finance Committee of its board of directors.
As the Independent Director of Regeneron Pharmaceuticals, the total compensation of N Coles at Regeneron Pharmaceuticals is $704,993. There are 22 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
N Coles is 60, he's been the Independent Director of Regeneron Pharmaceuticals since 2017. There are 14 older and 7 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis und Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: